- Home
- HBAN vs ALNY Comparison
HBAN vs ALNY Comparison
Compare HBAN & ALNY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | HBAN | ALNY |
|---|---|---|
| Founded | 1866 | 2002 |
| Country | United States | United States |
| Employees | N/A | 115 |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 36.3B | 30.1B |
| IPO Year | 2010 | 2004 |
Fundamental Metrics
Financial Performance| Metric | HBAN | ALNY |
|---|---|---|
| Price | $15.72 | $225.00 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 21 | 30 |
| Target Price | $19.17 | ★ $368.71 |
| AVG Volume (30 Days) | ★ 24.4M | 1.2M |
| Earning Date | 10-22-2026 | 10-29-2026 |
| Dividend Yield | ★ 3.96% | N/A |
| EPS Growth | 13.93 | ★ 206.88 |
| EPS | 0.25 | ★ 2.71 |
| Revenue | ★ $1,562,000,000.00 | $1,037,418,000.00 |
| Revenue This Year | $35.51 | $47.52 |
| Revenue Next Year | $7.09 | $25.98 |
| P/E Ratio | ★ $62.70 | $83.32 |
| Revenue Growth | 6.40 | ★ 22.88 |
| 52 Week Low | $14.82 | $197.81 |
| 52 Week High | $19.44 | $485.36 |
Technical Indicators
Market Signals| Indicator | HBAN | ALNY |
|---|---|---|
| Relative Strength Index (RSI) | 52.24 | 42.20 |
| Support Level | $14.95 | $223.61 |
| Resistance Level | $17.25 | $234.00 |
| Average True Range (ATR) | 0.30 | 7.66 |
| MACD | 0.11 | 0.19 |
| Stochastic Oscillator | 83.51 | 34.60 |
Price Performance
Historical ComparisonAbout HBAN Huntington Bancshares Incorporated
Huntington is a regional US bank with over $285 billion in assets. It offers a full suite of consumer deposit and lending services, along with commercial services focused on payments, investment management, capital markets, equipment financing, treasury management, and other common banking services.
About ALNY Alnylam Pharmaceuticals Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam's commercial RNAi therapeutic products include Onpattro and Amvuttra (for hATTR amyloidosis), Givlaari (for acute hepatic porphyria), and Oxlumo (for primary hyperoxaluria type 1), all developed and commercialized by Alnylam. Plus, Leqvio (for hypercholesterolemia) and Qfitlia (for hemophilia A or B), which are being commercialized by Alnylam's partners, Novartis and Sanofi, respectively. It also has several clinical programs across various therapeutic areas, including cardio-metabolic diseases, neuroscience, and hematology.